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Abstract
Background
The ratio of the diameter of the main pulmonary artery (mPA) to the diameter of the aorta
(Ao) on chest computed tomography is associated with diverse clinical conditions. Herein,
we determined the functional and prognostic implications of the mPA/Ao ratio in Korean
chronic obstructive pulmonary disease (COPD) patients.
Methods
The study population comprised 226 chronic obstructive pulmonary disease patients from
the Korean Obstructive Lung Disease cohort who underwent chest computed tomography.
We analyzed the relationships between the clinical characteristics, including pulmonary
function, echocardiography findings, St. George's Respiratory Questionnaire, 6-minute
walking (6MW) distance, and exacerbation with the mPA, Ao, and mPA/Ao ratio.
Results
The mean age was 65.8 years, and 219 (96.9%) patients were male. The mean FEV1% pre-
dicted and FEV1/FVC ratio were 61.2% and 47.3%, respectively. The mean mPA and Ao
were 23.7 and 36.4 mm, respectively, and the mPA/Ao ratio was 0.66. The mPA/Ao ratio
correlated negatively with the 6MW distance (G = -0.133, P = 0.025) and positively with the
right ventricular pressure (G = 0.323, P = 0.001). After adjustment for potential confounders,
the mPA/Ao ratio was significantly associated with 6MW distance (β = -107.7, P = 0.017).
Moreover, an mPA/Ao ratio >0.8 was a significant predictor of exacerbation at the 1-year
PLOS ONE | DOI:10.1371/journal.pone.0154584 May 6, 2016 1 / 13
a11111
OPEN ACCESS
Citation: Chung KS, Kim YS, Kim SK, Kim HY, Lee
SM, Seo JB, et al. (2016) Functional and Prognostic
Implications of the Main Pulmonary Artery Diameter
to Aorta Diameter Ratio from Chest Computed
Tomography in Korean COPD Patients. PLoS ONE
11(5): e0154584. doi:10.1371/journal.pone.0154584
Editor: Francesco Cappello, University of Palermo,
ITALY
Received: August 26, 2015
Accepted: April 17, 2016
Published: May 6, 2016
Copyright: © 2016 Chung et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: On the consent
received by the participants, the data are to be used
only for the research and are not to be opened to
public without permission from the KOLD cohort
study group. Requests for the data may be sent to
Soo Yeon Moon, the data manager of the Clinical
Research Center for Chronic Obstructive Airway
Diseases (oz09@naver.com).
Funding: This research was supported by a grant of
the Korea Healthcare technology R&D Project,
Ministry of Health and Welfare (HI10C2020 and
A102065) to SDL. The funder had no role in study
(odds ratio 2.12, 95% confidence interval 1.27–3.52) and 3-year follow-ups (odds ratio 2.04,
95% confidence interval 1.42–2.90).
Conclusions
The mPA/Ao ratio is an independent predictor of exercise capacity and an mPA/Ao ratio
>0.8 is a significant risk factor of COPD exacerbation.
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by progressive, irreversible
airflow limitations, resulting in disabling respiratory symptoms and devastating comorbidities.
Pulmonary hypertension (PH) occurs in severe COPD due to various mechanisms, including
hypoxic vasoconstriction, pulmonary hyperinflation with increased intrathoracic pressure, and
loss of pulmonary vascular capacity due to parenchymal destruction.[1–3] However, similar
changes can be recognized in mild COPD, suggesting that systemic vascular alterations such as
endothelial dysfunction are closely related with PH.[4,5]
PH is an important predictor of low exercise capacity, exacerbations, and mortality in
COPD.[6–8] However, PH in COPD is rarely diagnosed using right heart catheterization as the
gold standard, because of its relative invasiveness. Doppler echocardiography is a noninvasive
means of estimating systolic pulmonary artery pressure and diagnosing significant PH. More-
over, high negative predictive value may make echocardiography as one of the screening
modalities for PH in patients with severe emphysema. However, the hyperinflated lungs in
COPD may decrease its sensitivity.[9,10]
The ratio of the main pulmonary artery diameter (mPA) to the aorta diameter (Ao) on
chest computed tomography (CT) correlates with the invasive measures of pulmonary artery
pressure and is one useful method to detect PH.[11,12] Furthermore, relative pulmonary artery
enlargement (mPA/Ao ratio>1), as measured by chest CT, is associated with an increased risk
of COPD exacerbation and hospitalization.[13]
However, other clinical implications of the mPA/Ao ratio in COPD remain largely
unknown. Hence, we investigated the functional and prognostic implications of the mPA/Ao
ratio in a cohort of Korean COPD patients.
Materials and Methods
Study population
Two hundred twenty-six COPD patients from the Korean Obstructive Lung Disease (KOLD)
cohort, in which patients with COPD or asthma were enrolled from pulmonary clinics in 17
hospitals in South Korea from June 2005 to December 2012, were included in the present
study. The inclusion criteria were as follows: post-bronchodilator ratio of forced expiratory vol-
ume in 1 second to forced vital capacity (FEV1/FVC)<0.7, age over 40 years, smoking history
of 10 or more pack-years, no or minimal abnormality on chest radiography, and available chest
CT data. Of the 226 participants, 205 (90.7%) and 171 (75.7%) had completed 1 and 3 years of
follow-up, respectively. This study was conducted in accordance with the amended Declaration
of Helsinki. The Institutional Review Boards of the 17 hospitals included in the KOLD cohort
approved the protocol and written informed consent was obtained from all patients: Asan
Medical Center IRB (2012–0226), Hanyang University Guri Hospital IRB (2012–016), Inje
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design, data collection and analysis, decision to
publish, or preparation of the manuscript.
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University Ilsan Paik Hospital IRB (05–06), Bundangcha Hospital IRB (2005–017), Kangbook
Samsung Medical Center IRB (2005–19), Ewha Womans University Mokdong Hospital IRB
(106–02), Kangwon National University Hospital IRB (05–01), Korea University Anam Hospi-
tal IRB (254), Seoul National University Hospital IRB (H-0505-148-013), Seoul National Uni-
versity Bundang Hospital IRB (B-05081023-009), Hallym University Medical Center IRB
(2005–9), Konkuk University Medical Center IRB (KUH 1010210), Ajou University Hospital
IRB (10–237), National Medical Center IRB (CM-KOLD-1109), The Catholic University of
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Clinical characteristics of COPD
Data on demographics, smoking status, underlying diseases, pulmonary function test,
St. George's Respiratory Questionnaire (SGRQ), 6-minute walking (6MW) distance, exacerba-
tions, transthoracic echocardiographic measurements (ejection fraction and right ventricular
pressure [RVP]), and chest CT measurements (airway index, air trapping, and emphysema
index) were analyzed for their relationships with the mPA, Ao, and mPA/Ao ratio. Exacerba-
tion was defined as aggravation of at least 1/3 respiratory symptoms (dyspnea, cough, or spu-
tum purulence) for2 days that required an unscheduled visit to hospital or emergency room,
or hospitalization for additional treatment. Patients were interviewed at the clinic every 3
months with the pre-structured interview sheet including the question if they have visited clin-
ics or emergency rooms due to increased sputum amount, purulent sputum, or deterioration of
dyspnea within 3months. Exacerbation documented in the hospital where the patients were
enrolled, was traced by medical records. If the patients visited other clinics or other emergency
rooms, we collected the name of clinics or emergency rooms, reason for visit, visit date, and fre-
quency through the pre-structured interview sheet.
Chest CT measurements
Volumetric CT scans were performed on all patients in the beginning of the enrollment during
stable disease status at full inspiration and expiration using a 16-multi detector CT scanner
(Somatom Sensation; Siemens Medical System, Erlangen, Germany). Two radiologists inde-
pendently measured the mPA and Ao. The mPA and Ao at the level of bifurcation were used to
calculate the mPA/Ao ratio. mPA was determined by the widest diameter perpendicular to the
long axis of the main pulmonary artery at the level of pulmonary artery bifurcation. The Ao
was determined by the transverse diameter of the aorta at the level of pulmonary artery bifurca-
tion. The κ value of the intraclass correlation coefficient was 0.95 (95% confidence interval
(CI), 0.93–0.96) for mPA, and 0.94 (95% CI, 0.92–0.95) for Ao.
For the airway index, air trapping, and emphysema index, images of the whole lung were
extracted automatically and the attenuation coefficient of each pixel was calculated. The cut-off
level between normal lung density and low-attenuation areas was defined as -950 Hounsfield
units.[14] The volume fraction of the lung below -950 Hounsfield units was calculated auto-
matically at full inspiration, and termed the emphysema index. The mean lung density was cal-
culated automatically during expiration and inspiration. The air-trapping index was estimated
by calculating the ratio of the mean lung density at expiration and inspiration. Airway dimen-
sions were measured near the origin of the two segmental bronchi (RB1, LB1+2). The airway
dimensions (wall area, lumen area, and wall area percent [15]) were measured in each bron-
chus. The airway index (wall area percent) was defined as wall area/ (wall area + lumen area) ×
100.[16]
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Statistical analysis
Statistical analysis was performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). The cor-
relations between clinical characteristics and the mPA, Ao, and mPA/Ao ratio were analyzed.
Multivariate linear regression analyses adjusted for age, body surface area (BSA), lung function,
and SGRQ were performed to evaluate the effects of mPA, Ao, and the mPA/Ao ratio on the
6MW distance. We defined patients with an mPA/Ao ratio>0.8 and0.8 as the high and low
groups, respectively. An mPA/Ao ratio of>0.8 was considered to indicate the presence of rela-
tive pulmonary artery enlargement, as this represents the top 10 percentile in the distribution.
The baseline characteristics are summarized using percentages to describe categorical variables,
and the two groups (mPA/Ao ratio0.8 vs.>0.8) were compared using chi-square analyses.
Continuous variables are presented as median (interquartile range), as assessed by the Mann-
Whitney nonparametric U test. Differences in COPD exacerbation during the follow-up period
were analyzed with logistic regression analysis for repeated measures using Generalized Esti-
mating Equations. The risk of exacerbation is described as the odds ratio (OR) with 95% confi-
dence interval (CI). In all analyses, P-values<0.05 were deemed statistically significant.
Results
Baseline characteristics of study population
The mean age was 65.8 years, and 219 (96.9%) patients were male. The FEV1, FVC, and FEV1/
FVC were 1.64 L, 3.46 L, and 47.3%, respectively. According to the previous Global initiative
for Chronic Obstructive Lung Disease criteria, 15.9%, 53.1%, 26.1%, and 4.9% of patients were
categorized as mild, moderate, severe, and very severe, respectively. The mPA and Ao were
23.7 and 36.4 mm, respectively, and the mPA/Ao ratio was 0.66 (Table 1). None of the patients
showed an mPA/Ao ratio>1.
Clinical characteristics/CT correlations
Table 2 demonstrates the correlations between the clinical characteristics and the mPA, Ao,
and mPA/Ao ratio. Age and BSA positively associated with mPA (G = 0.154, P = 0.02;
G = 0.154, P = 0.02) and Ao (G = 0.257, P<0.001; G = 0.228, P = 0.001). The 6MW distance
negatively associated with the mPA (G = -0.124, P = 0.034) and mPA/Ao ratio (G = -0.133,
P = 0.025). Moreover, the RVP on echocardiography positively associated with the mPA
(G = 0.327, P = 0.001) and mPA/Ao ratio (G = 0.323, P = 0.001).
Multivariate analysis for 6MW distance
Table 3 shows the multivariate linear analyses to determine the relationships of the mPA, Ao,
and mPA/Ao with the 6MW distance. After adjustment for age, BSA, FEV1% predicted, FEV1/
FVC, and SGRQ total score, the mPA/Ao ratio was significantly associated with 6MW distance
(β = -107.7, P = 0.017). In all three models, age, BSA, and SGRQ were significantly related with
the 6MW distance.
mPA/Ao ratio vs.> 0.8. Among the 226 COPD patients, 210 (92.9%) and 16 (7.1%)
were classified as low (mPA/Ao ratio0.8) and high (mPA/Ao ratio>0.8) groups, respectively
(Table 4). The age, proportion of males, and BSA did not differ between the groups. The
amount of smoking was higher (44 vs. 32.5 pack-years, P = 0.024), congestive heart failure and
myocardial infarction were more common, and diabetes mellitus and asthma were less com-
mon in the low group. Other clinical characteristics of COPD did not differ between the two
groups. The mPA and Ao were larger in the high group (28.4 vs. 23.3 mm, P<0.001 and 36.4
vs. 34.2 mm, P = 0.008, respectively), as was the RVP (34.0 vs. 27.9 mmH2O, P = 0.029).
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Associations between mPA/Ao and exacerbations
Logistic regression analyses to identify clinical factors associated with exacerbation of COPD
revealed that an mPA/Ao ratio>0.8 correlated with exacerbations at the 1-year (OR = 3.51,
Table 1. Baseline characteristics of the patientsa.
Baseline characteristics Total
(n = 226)
Age, years 65.8 ± 7.5
Male sex 219 (96.9)
BMI, kg/m2 23.3 ± 3.3
BSA, m2 1.70 ± 0.15
Smoking amount, pack-years 46.7 ± 24.9
Current smoker 72 (31.9)
Underlying diseases
Congestive heart failure 4 (1.8)
Myocardial infarction 4 (1.8)
Hypertension 59 (26.1)
Diabetes mellitus 23 (10.2)
Asthma 56 (24.8)
Pulmonary function tests
FEV1, L 1.64 ± 0.56
FEV1, % predicted 61.2 ± 19.1
FVC, L 3.46 ± 0.80
FVC, % predicted 91.3 ± 18.3
FEV1/FVC, % 47.3 ± 11.0
DLco, % predicted (n = 221) 80.7 ± 25.1
RV, % predicted (n = 213) 147.1 ± 57.6
TLC, % predicted (n = 208) 117.5 ± 20.5
RV/TLC, % (n = 208) 47.9 ± 12.9
SGRQ, total score 33.4 ± 17.6
6MW distance, m (n = 217) 447.0 ± 74.9
Oxygen saturation, % 96.3
Exacerbation in previous year 41 (18.1)
Chest computed tomography parameters
mPA, mm 23.7 ± 3.3
Ao, mm 36.4 ± 3.6
mPA/Ao ratio 0.66 ± 0.09
Airway index (n = 221) 66.1 ± 6.3
Air trapping, % (n = 221) 94.4 ± 3.4
Emphysema index (n = 221) 22.8 ± 15.2
Echocardiography
Ejection fraction, % (n = 62) 61.3 ± 5.7
Right ventricular pressure, cmH2O (n = 107) 29.0 ± 7.9
a Data are presented as numbers (percentages) for categorical variables. Continuous variables are
presented as means ± standard deviations.
BMI, body mass index; BSA, body-surface area; FEV1, forced expiratory volume in 1s; FVC, forced vital
capacity; DLco, diffusion capacity of carbon monoxide; RV, residual volume; TLC, total lung capacity;
SGRQ, St. George's Respiratory Questionnaire; 6MW, 6-minute walking; mPA, main pulmonary artery
diameter; Ao, aorta diameter.
doi:10.1371/journal.pone.0154584.t001
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95% CI 1.37–9.02, P = 0.009) and 3-year follow-ups (OR = 2.1, 95% CI 1.22–3.56, P = 0.007)
(Table 5). Exacerbation history in the previous year was also related with exacerbations at the
1-year (OR = 2.12, 95% CI 1.27–3.52, P = 0.004) and 3-year follow-ups (OR = 2.04, 95% CI
1.42–2.90, P<0.001). Conversely, the SGRQ score showed inverse relationships with COPD
exacerbation at both follow-ups.
Discussion
Herein, we found that the mPA/Ao ratio independently correlated with exercise capacity
(6MW distance) and that an mPA/Ao ratio>0.8 was an independent risk factor for exacerba-
tion at the 1-year and 3-year follow-ups in Korean COPD patients. Moreover, RVP related
with the mPA/Ao ratio, while the pulmonary function, airway index, air trapping, and emphy-
sema index did not.
The prevalence of PH in COPD patients ranges between 30–70%, and often develops in
advanced COPD.[17] COPD-associated PH has significant clinical implications such as func-
tional limitations and poor prognosis, with a 5-year survival rate of 20–36%.[17–19] Severe
PH, defined as mean pulmonary arterial pressure (mPAP)>40 mmHg, can also present in
mild-to-moderate COPD patients, who show worse mortality than those with mild-to-
Table 2. Correlations between clinical characteristics and chest CT parameters.
Clinical characteristics mPA Ao mPA/Ao ratio
G P-value G P-value G P-value
Age, years 0.154 0.02 0.257 <0.001 -0.033 0.623
BMI, kg/m2 0.162 0.015 0.141 0.034 0.061 0.359
BSA, m2 0.154 0.02 0.228 0.001 -0.006 0.931
Pulmonary function tests
FEV1, L -0.016 0.245 0.014 0.416 -0.045 0.249
FEV1, % predicted -0.014 0.416 0.017 0.4 -0.018 0.395
FVC, L -0.083 0.107 -0.043 0.26 -0.047 0.239
FVC, % predicted -0.049 0.234 -0.109 0.05 0.031 0.324
FEV1/FVC, % 0.005 0.469 0.067 0.157 -0.031 0.32
DLco, % predicted (n = 221) 0.008 0.453 0.06 0.186 -0.035 0.304
RV, % predicted (n = 213) -0.014 0.423 -0.09 0.099 0.041 0.28
TLC, % predicted (n = 208) 0.004 0.48 -0.008 0.455 0.002 0.491
RV/TLC, % (n = 208) 0.063 0.184 0.107 0.061 -0.024 0.364
SGRQ, total score 0.012 0.427 -0.34 0.304 0.035 0.3
6MW distance, m (n = 217) -0.124 0.034 0.032 0.322 -0.133 0.025
Oxygen saturation, % -0.032 0.642 -0.085 0.211 0.022 0.753
Chest computed tomography parameters
Airway index 0.01 0.443 -0.006 0.467 0.013 0.423
Air trapping -0.007 0.459 0.055 0.208 -0.053 0.215
Emphysema index -0.055 0.207 -0.189 0.002 0.077 0.127
Echocardiographyb
Ejection fraction, % (n = 62) -0.101 0.434 -0.086 0.508 0.002 0.986
Right ventricular pressure, cmH2O (n = 107) 0.327 0.001 0.001 0.998 0.323 0.001
CT, computed tomography; mPA, main pulmonary artery diameter; Ao, aorta diameter; BMI, body mass index; BSA, body surface area; FEV1, forced
expiratory volume in 1s; FVC, forced vital capacity; DLco, diffusion capacity of carbon monoxide; RV, residual volume; TLC, total lung capacity; SGRQ, St
George's Respiratory Questionnaire; 6MW, 6-minute walking.
doi:10.1371/journal.pone.0154584.t002
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moderate PH (mPAP, 20–40 mmHg).[8] PH is disproportionate to the degree of airflow limita-
tion, because pulmonary vascular changes can appear at the early stages of disease and in
smokers without airflow limitation.[15,20] An experimental study with animal models of
COPD revealed that changes in the pulmonary vessels occurred prior to development of
emphysema,[21] and PH observed in non-severe COPD is considered the combined result of
systolic and diastolic left ventricular failure, inflammation, and other comorbid conditions.
[22,23]
CT is a useful, non-invasive tool for evaluating both intrinsic lung disease and intrathoracic
vasculature in COPD patients. Recently, extensive researches on the usefulness of CT in COPD
have been conducted regarding the coronary artery calcium score, lung cancer screening, and
pulmonary emphysema subtyping.[24–26] However, these evaluations may need specialized
software and expertise, while the mPA/Ao ratio is readily measurable by chest CT and requires
minimal training with good inter-observer and intra-observer agreements.[11,13,27,28] The
two radiologists in our study also showed excellent agreements with k value of more than 0.9.
Moreover, the mPA/Ao ratio has been shown to correlate with mPAP (γ = 0.74, P<0.001) and
to suggest diverse clinical conditions.[29,30] The sensitivity and specificity of the mPA/Ao
ratio>1 to predict mPAP>25 mmHg have been reported as 68.4–96.0% and 59.0–92.0%,
respectively, in various population.[11,22,30–32] According to the report of Iyer et al., mPA/
Ao ratio>1 showed sensitivity of 73% and specificity of 84% for identifying resting PH in
patients with COPD.[11] In this study, we furthermore demonstrated a significant, albeit
weaker correlation than in previous reports, between the RVP and mPA/Ao ratio (γ = 0.323,
Table 3. Multivariate linear analyses for the effects of clinical characteristics, including chest CT parameters, on the 6MWdistance (n = 217).
Clinical characteristics β P-value 95% CI
Model 1
Age, years -2.915 < 0.001 -1.08 –-1.75
BSA, m2 88.524 0.006 25.16–151.88
FEV1, % predicted .138 0.694 -0.55–0.83
FEV1/FVC, % .311 0.604 -0.87–1.49
SGRQ, total score -1.388 < 0.001 -1.91 –-0.87
mPA, mm -2.427 0.065 -5.00–0.15
Model 2
Age, years -3.322 < 0.001 -4.53 –-2.11
BSA, m2 65.785 0.047 0.80–130.77
FEV1, % predicted .194 0.583 -0.50–0.89
FEV1/FVC, % .289 0.632 -0.89–1.47
SGRQ, total score -1.403 < 0.001 -1.93 –-0.88
Ao, mm 1.469 0.245 -1.02–3.95
Model 3
Age, years -3.162 < 0.001 -4.31 –-2.02
BSA, m2 76.917 0.015 15.19–138.65
FEV1, % predicted .181 0.603 -0.51–0.87
FEV1/FVC, % .262 0.66 -0.91–1.43
SGRQ, total score -1.389 < 0.001 -1.91 –-0.87
mPA/Ao ratio -107.717 0.017 -195.69 –-19.74
CT, computed tomography; 6MW, 6-minute walking; CI, conﬁdence interval; BSA, body-surface area; FEV1, forced expiratory volume in 1s; FVC, forced
vital capacity; SGRQ, St. George's Respiratory Questionnaire; mPA, main pulmonary artery diameter; Ao, aorta diameter.
doi:10.1371/journal.pone.0154584.t003
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Table 4. Clinical characteristics of patients with mPA/Ao ratio0.8 andmPA/Ao ratio>0.8a.
Clinical characteristics mPA/Ao ratio  0.8 mPA/Ao ratio > 0.8 P-value
(n = 210) (n = 16)
Age, years 67.0 (61.0–70.0) 65.5 (60.1–68.8) 0.629
Male sex 204 (97.1) 15 (93.8) 0.450
BMI, kg/m2 23.4 (21.0–25.4) 23.7 (22.1–25.8) 0.346
BSA, m2 1.71 (1.61–1.80) 1.70 (1.64–1.76) 0.954
Smoking history, pack-years 44.0 (29.8–55.5) 32.5 (21.4–40.5) 0.024
Current smoker 69 (32.9) 3 (18.8) 0.479
Underlying disease
Congestive heart failure 4 (1.9) 0 (0) 0.001
Myocardial infarction 4 (1.9) 0 (0) 0.004
Hypertension 54 (25.7) 5 (31.2) 0.831
Diabetes mellitus 21 (10.4) 2 (12.5) 0.013
Asthma 50 (24.9) 6 (37.5) 0.024
Tuberculosis 37 (18.4) 2 (12.5) 0.836
Gastroesophageal reﬂux disease 3 (1.5) 0 (0) 0.183
Pulmonary function tests
FEV1, L 1.6 (1.2–2.0) 1.7 (1.1–1.9) 0.835
FEV1, % predicted 59.5 (47.0–76.0) 62.5 (47.0–68.7) 0.861
FVC, L 3.4 (2.9–4.0) 3.1 (2.8–3.9) 0.398
FVC, % predicted 90.5 (78.0–103.3) 89.0 (75.8–103.8) 0.793
FEV1/FVC, % 48.0 (40.0–56.0) 47.0 (40.2–56.8) 0.896
Severity of airway obstructionb 0.510
Mild 35 (16.7) 1 (6.3)
Moderate 110 (52.4) 10 (62.5)
Severe or very severe 65 (30.9) 5 (31.3)
SGRQ, total score 29.6 (20.3–46.6) 36.6 (22.4–41.2) 0.511
6MW distance, m 454.5 (400.0–497.5) 427.5 (405.0–467.5) 0.254
Oxygen saturation, % 97.0 (95.0–98.0) 96.0 (95.3–97.0) 0.693
Exacerbation in previous year 36 (17.1) 5 (31.3) 0.359
CT
mPA, mm 23.3 (21.6–25.4) 28.4 (26.7–29.6) <0.001
Ao, mm 36.4 (33.8–39.1) 34.2 (32.1–35.6) 0.008
Airway index 66.2 (62.3–69.6) 66.9 (65.6–69.9) 0.226
Air trapping 94.8 (92.7–96.7) 95.2 (91.7–96.7) 0.733
Emphysema index 20.1 (9.9–34.4) 21.7 (7.1–39.2) 0.790
Echocardiography
Ejection fraction, %c 62.0 (59.0–64.0) 62.0 (60.0–68.5) 0.300
Right ventricular pressure, cmH2O
d 27.9 (23.0–33.0) 34.0 (29.3–41.6) 0.029
a Data are presented as numbers (percentages) for categorical variables. Continuous variables are presented as median (interquartile range).
b The severity of airway obstruction was based upon the percent of predicted FEV1 in accordance with the previous GOLD criteria (FEV1 80% predicted,
mild; FEV1 = 50~79% predicted, moderate; FEV1 = 30~49% predicted, severe; FEV1 <30% predicted, very severe).
c Echocardiography data were available in 57 patients with PA:A ratio 0.8 and in 5 patients with PA:A ratio >0.8.
d Echocardiography data were available in 98 patients with PA:A ratio 0.8 and in 9 patients with PA:A ratio >0.8.
mPA, main pulmonary artery diameter; Ao, aorta diameter; BMI, body mass index; BSA, body surface area; CT, computed tomography; SGRQ,
St. George's Respiratory Questionnaire; 6MW, 6-minute walking.
doi:10.1371/journal.pone.0154584.t004
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P = 0.001) in COPD patients.[13] Unfortunately, assessment of the predictive value of mPA/
Ao ratio>1.0 for PH was not possible, because no patient showed such elevation.
In the COPDGene study, relative pulmonary artery enlargement (mPA/Ao ratio>1) was a
useful biomarker for future exacerbation events in COPD.[13] Patients with an mPA/Ao ratio
>1 group were more frequently female; had higher body mass index (BMI), worse airflow
obstruction, and more common supplemental oxygen use; and showed higher prevalence of
congestive heart failure and thromboembolic disease. On the other hand, Iyer et al. reported a
higher prevalence of congestive heart failure in patients with an mPA/Ao ratio>1, but no dif-
ference in airflow obstruction.[11] In our study, the mPA/Ao>0.8 group less frequently
showed cardiac diseases such as congestive heart failure and myocardial infarction, but more
frequently experienced diabetes mellitus or asthma. However, because of the small number of
cardiac diseases, no firm conclusions could be drawn. Moreover, the lung function and other
quantitative assessments on chest CT did not differ between the groups and did not correlate
with the mPA, Ao, or mPA/Ao ratio. This finding is in accordance with previous reports that
lung function has no utility in the prediction of mPAP in COPD.[23,33,34]
Besides the relationship of the mPA/Ao ratio with hemodynamics, we investigated the prog-
nostic and functional predictive roles of the mPA/Ao ratio in COPD. Wells et al. reported an
mPA/Ao ratio>1 as a significant predictor of severe exacerbation in the COPDGene and Eval-
uation of COPD Longitudinally to Identify Predictive Surrogate Endpoints cohorts during 3
years of follow-up.[13] Herein, we provided further evidence of the prognostic role of elevated
mPA/Ao ratio, even at a subclinical level (>0.8), for COPD exacerbation in Korea.
Subclinical levels of mPA/Ao in Korean COPD may have shown clinical implication
because our cohort study population had relatively lower distribution of mPa/Ao ratio. This
distinct distribution can be explained by several clinical characteristics in our study population.
BMI and BSA were relatively lower in our study (BMI: 23.3 kg/m2 and BSA: 1.7m2) compared
with those in other studies (BMI: 25–28 kg/m2 and BSA: 1.8–1.9 m2) of various diseases.
[11,27,28,35–38] Wells et al. showed that COPD patients with mPA/Ao>1 had higher BMI
(29.7 ± 7 kg/m2).[13] Moreover, according to COPD stages, proportion of supplemental oxy-
gen use and comorbidities, the severity of disease was lower in our study population.[13,39,40]
More patients in our study were categorized into mild-moderate group more (69%) and less
into very severe group (4.9%) than those in COPDGene study (52.9% and 15.6%) and ECLIPSE
study (44.2% and 13.7%). Moreover, proportion of supplemental oxygen use was higher in
COPDGene study (27%) while none used it in our study.[13] For the comorbidities, number of
patients with hypertension (50%) and congestive heart failure (5–7%) was higher in other
Table 5. Clinical factors associated with COPD exacerbations in the KOLD cohort.
Clinical factors 1-year follow-upa 3-year follow-upb
OR 95% CI P-value OR 95% CI P value
Exacerbation in previous year 2.12 1.27–3.52 0.004 2.04 1.42–2.90 <0.001
FEV1, % predicted, 1-percentage increase 1.01 0.99–1.02 0.222 1 0.99–1.01 0.432
SGRQ, 1-point increase 0.99 0.97–1.00 0.035 0.98 0.97–0.99 <0.001
Age, 1-year increase 0.99 0.96–1.02 0.523 0.99 0.97–1.02 0.508
mPA/Ao ratio, >0.8 3.51 1.37–9.02 0.009 2.1 1.22–3.56 0.007
a n = 205
b n = 171
COPD, chronic obstructive pulmonary disease; KOLD, Korean obstructive lung disease; OR, odds ratio; CI, conﬁdence interval; FEV1, forced expiratory
volume in 1s; SGRQ, St. George's Respiratory Questionnaire; mPA, main pulmonary artery diameter; Ao, aorta diameter.
doi:10.1371/journal.pone.0154584.t005
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studies than our study (26% and 2%).[13,39] Lastly, different ethnicities are also important fac-
tors. While our study population consisted of only Koreans, the proportion of Asians was none
or small in other studies. Therefore, subclinical levels of mPA/Ao may reveal clinical impor-
tance in different population.
Although the mechanisms of the relationship between exacerbation and increased mPA/Ao
ratio requires clarification, repetition of subclinical exacerbation associated with transient
increases in the mPAP could lead to permanent vascular remodeling, which consequently may
cause future exacerbation and poor prognosis.[23,41] Moreover, vascular remodeling may
lower the threshold of hemodynamic stability and make the patients vulnerable to
exacerbation.
Finally, among the limited data on the relationship between PH and exercise function in
COPD, Sims et al. determined that higher systolic pulmonary arterial pressure was indepen-
dently associated with reduced exercise function in severe COPD.[6] This is the first study to
demonstrate that a higher mPA/Ao ratio was associated with significantly lower exercise
impairment, that is, a shorter 6MW distance, independent of demographic factors and lung
function (Table 3). Wells et al. also reported that the 6MW distance negatively correlated with
the mPA/Ao ratio (G = -0.49, P = 0.02).[37] However, on multivariate logistic regression analy-
sis, as the 6MW distance decreased by 1 foot, the OR for mPA/Ao ratio>1 was 1 (95% CI
1.00–1.01). Pulmonary vascular remodeling in COPD may result in ventilation–perfusion mis-
match, leading to worsening of hypoxemia and failure of the pulmonary vascular bed to
accommodate the increased cardiac output during exercise.[6] Further, early right ventricular
changes in non-severe COPD are associated with lower exercise tolerance.[35]
The strengths of our study are that it was the first study to determine the functional and
prognostic impacts of the mPA/Ao ratio, which is easily measurable on chest CT, using the
KOLD cohort. However, there were some limitations. First, the number of included patients
was relatively small, even though this was a multicenter observational study. Second, over half
the patients showed a moderate degree of airflow obstruction, so our finding might not be
applicable to patients with severe airway obstruction. However, in contrast to the previous
studies on COPD patients with severe severity, we have demonstrated clinical significance of
mPA/Ao ratio in relation to exacerbation and exercise capacity in COPD patients with less
severity. Third, the mean mPA/Ao ratio was relatively low compared to in previous studies.
The mPA and Ao independently correlate with age and body size, leading to decreases in the in
mPA/Ao ratio with aging and lower body size as compared with the general population and
COPD patients of other ethnicities.[27,29,42] Fourth, 0.8 was used as the cut-off of the mPA/
Ao ratio and was the best values to predict acute exacerbation of Korean COPD patients; how-
ever, its clinical utility for individual patients should be taken with caution. Lastly, information
on nocturnal symptoms or symptoms of sleep apnea was not collected in the cohort. Obstruc-
tive sleep apnea is related with higher PA pressure and PH is a poor prognostic sign in patients
with obstructive sleep apnea.[43]
Conclusion
Herein, the functional and prognostic implications of the mPA/Ao ratio were evaluated in the
KOLD cohort. The mPA/Ao ratio was an independent negative predictor of functional capac-
ity, measured by the 6MW distance. This finding may help predict the exercise capacity in
COPD patients unable to fully perform exercise tolerance tests for various reasons. Moreover,
we showed that an mPA/Ao ratio>0.8 was a significant predictor of COPD exacerbation at 1
and 3 years. Nevertheless, the role of mPA/Ao for monitoring the therapeutic response requires
further study.
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